DrugPatentWatch Database Preview

Cumberland Pharms Company Profile

CUMBERLAND PHARMS has seven approved drugs.

There are twenty-seven US patents protecting CUMBERLAND PHARMS drugs.

There are two hundred and eight patent family members on CUMBERLAND PHARMS drugs in forty countries and fourteen supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-001	Sep 11, 2009		DISCN	Yes	No	6,872,701	Start Trial	Y			Start Trial
Cumberland Pharms	ACETADOTE	acetylcysteine	INJECTABLE;INTRAVENOUS	021539-001	Jan 23, 2004	AP	RX	Yes	Yes	8,722,738	Start Trial				Start Trial
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-003	Jan 25, 2019		RX	Yes	Yes	9,072,710	Start Trial				Start Trial
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes	7,531,623	Start Trial		Y		Start Trial
Cumberland Pharms	REDITREX	methotrexate	SOLUTION;SUBCUTANEOUS	210737-003	Nov 27, 2019		RX	No	No		Start Trial				Start Trial
Cumberland Pharms	VIBATIV	telavancin hydrochloride	POWDER;INTRAVENOUS	022110-002	Sep 11, 2009		RX	Yes	Yes	8,158,580	Start Trial	Y			Start Trial
Cumberland Pharms	CALDOLOR	ibuprofen	SOLUTION;INTRAVENOUS	022348-003	Jan 25, 2019		RX	Yes	Yes	9,072,661	Start Trial				Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cumberland Pharms	VAPRISOL	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-001	Dec 29, 2005	5,723,606	Start Trial
Cumberland Pharms	VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER	conivaptan hydrochloride	INJECTABLE;INTRAVENOUS	021697-002	Oct 8, 2008	5,723,606	Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	200 mg/mL, 30 mL vials	➤ Subscribe	2012-04-04

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1292612	1190036-2	Sweden	Start Trial	PRODUCT NAME: TELAVANCIN ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV INNEFATTANDE TELAVANCINHYDROKLORID; REG. NO/DATE: EU/1/11/705/001 20110902
1292612	91908	Luxembourg	Start Trial	91908, EXPIRES: 20260501
1292612	2011C/045	Belgium	Start Trial	PRODUCT NAME: VIBATIV - TELAVANCINE; AUTHORISATION NUMBER AND DATE: EU/1/11/705-001 20110902
1292612	11C0051	France	Start Trial	PRODUCT NAME: TELAVANCINE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
1292612	CA 2011 00033	Denmark	Start Trial	PRODUCT NAME: TELAVANCIN, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER TELAVANCIN HYDROCHLORID
1292612	2011/037	Ireland	Start Trial	PRODUCT NAME: TELAVANCIN, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TELAVANCIN HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
1292612	36/2011	Austria	Start Trial	PRODUCT NAME: TELAVANCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON, EINSCHLIESSLICH TELAVANCINHYDROCHLORID; REGISTRATION NO/DATE: EU/1/11/705/001-002 20110902
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.